It was only the day after Christmas when I mentioned that Tekmira (TKMR)
was a name that investors should think about investigating as a
potentially cheaper play on RNA interference (RNAi) than better-known
representatives of the class like Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals (ISIS). The stock had done pretty well since then (up about 20% in two weeks), but news of a deal with Monsanto (MON) gave another boost to the shares.
Now
I'm starting to wonder if things are getting a little too crazy in
RNAi-land. Alnylam was up very strongly on news of its partnership with Sanofi (SNY)
and Tekmira too was up more than one-third in the peak of excitement
over the Monsanto deal. Don't get me wrong, I think the Monsanto
agreement is a nice feather in the company's cap and something that
could become meaningful in a couple of years. I just think it's a little
bold for the Street to factor in 50% of the deal value as more or less a
given.
Read more here:
Tekmira Rides A Big Day In RNAi
No comments:
Post a Comment